Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [ 177 Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase 2 Trial. Lancet Oncol 2024;25:99-107.